Clinical Trials Browser

Phase 1 × onartuzumab × Clear all

NCT01068977 2017-05-19

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Solid Cancers

NCT02031731 2017-03-14

The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Neoplasms

NCT01897038 2016-11-02

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01974258 2016-11-02

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Phase 1 Withdrawn

Neoplasms